Thr228
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr228  -  VEZATIN (human)

Site Information
ALRLIQEtEVIsRGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23072324

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 1 ) , acute myeloblastic leukemia, without maturation (M1) ( 1 ) , liver cancer ( 2 ) , hepatocellular carcinoma ( 2 ) , B cell lymphoma ( 1 ) , non-Hodgkin's lymphoma ( 1 ) , multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:

References 

1

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

2

Tucker M (2008) CST Curation Set: 5485; Year: 2008; Biosample/Treatment: cell line, SNU-182/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info